• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Dyne Therapeutics, Inc. - Common Stock (NQ:DYN)

20.94 +0.33 (+1.60%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,436,287
Open 20.96
Bid (Size) 20.00 (2,000)
Ask (Size) 21.95 (400)
Prev. Close 20.61
Today's Range 20.42 - 21.62
52wk Range 8.060 - 25.00
Shares Outstanding 58,310,703
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Dyne Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗
Today 11:25 EDT
Dyne is advancing therapies for rare muscle diseases while Viking targets the booming weight-loss market. See how their financials and risk profiles compare. 
Via The Motley Fool
News headline image
Dyne Therapeutics Appoints Barry Greene to Board of Directors
June 22, 2026
From Dyne Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+13.2%
+13.2%
1 Month
+15.4%
+15.4%
3 Month
+12.9%
+12.9%
6 Month
+4.5%
+4.5%
1 Year
+101.0%
+101.0%

More News

Read More
News headline image
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 18, 2026
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Dyne Therapeutics Inc (NASDAQ:DYN) Reports Narrower-Than-Expected Q4 2025 Loss, Reaffirms Key Clinical Timelines ↗
March 02, 2026
Via Chartmill
News headline image
Dyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc.
June 17, 2026
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 (DM1)
June 03, 2026
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge ↗
May 30, 2026
Via The Motley Fool
News headline image
Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean ↗
May 30, 2026
Via The Motley Fool
News headline image
Dyne Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)
May 26, 2026
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 20, 2026
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) Ahead of Planned BLA Submission for U.S. Accelerated Approval
May 20, 2026
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares ↗
May 19, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Dyne Therapeutics to Participate in Upcoming Investor Conferences
May 13, 2026
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
May 11, 2026
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Announces Upcoming Presentation Highlighting Robust CNS Activity in Nonhuman Primates with its FORCE™ Platform at 2026 ASGCT Annual Meeting
April 27, 2026
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 23, 2026
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Announces Participation at 2026 Academy of Managed Care Pharmacy (AMCP) Conference to Begin Shaping Access in US for Potential Neuromuscular Medicines
April 01, 2026
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
This Biotech Was Quietly Bought Before a $58 Per Share Takeout ↗
March 21, 2026
Via The Motley Fool
News headline image
Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1)
March 08, 2026
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)
March 08, 2026
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Investment Firm Adds Nearly $4 Milllion Worth of DYN Shares, According to Recent SEC Filing ↗
March 02, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Dyne Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
March 02, 2026
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics to Participate in Upcoming Investor Conferences
February 25, 2026
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Announces Upcoming Presentations Across Neuromuscular Pipeline at 2026 MDA Clinical & Scientific Conference
February 22, 2026
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1
January 20, 2026
From Dyne Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Dyne Therapeutics, Inc. - Common Stock publicly traded?
Yes, Dyne Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Dyne Therapeutics, Inc. - Common Stock trade on?
Dyne Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Dyne Therapeutics, Inc. - Common Stock?
The ticker symbol for Dyne Therapeutics, Inc. - Common Stock is DYN on the Nasdaq Stock Market
What is the current price of Dyne Therapeutics, Inc. - Common Stock?
The current price of Dyne Therapeutics, Inc. - Common Stock is 20.94
When was Dyne Therapeutics, Inc. - Common Stock last traded?
The last trade of Dyne Therapeutics, Inc. - Common Stock was at 06/26/26 04:00 PM ET
What is the market capitalization of Dyne Therapeutics, Inc. - Common Stock?
The market capitalization of Dyne Therapeutics, Inc. - Common Stock is 1.22B
How many shares of Dyne Therapeutics, Inc. - Common Stock are outstanding?
Dyne Therapeutics, Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap